MedTrace Logo

A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects

NCT06310876 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-07-01

No results posted yet for this study

Summary

This is a randomized, blinded, placebo and active-controlled, 4-period, crossover design thorough QT/QTc (TQT) study to evaluate the effect of ABBV-CLS-7262 on cardiac repolarization in healthy adult subjects.

Conditions

  • Healthy

Interventions

DRUG

ABBV-CLS-7262

• single oral Dose 1

DRUG

ABBV-CLS-7262

• single oral Dose 2

DRUG

Placebo

• single oral dose

DRUG

Moxifloxacin 400mg

• single oral dose

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Calico Life Sciences LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-14
Primary Completion
2024-05-29
Completion
2024-06-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06310876 on ClinicalTrials.gov